CytRx reports further evidence in support of aldoxorubicin

|About: CytRx Corporation (CYTR)|By:, SA News Editor

CytRx (CYTR) is out with more data in support of aldoxorubicin efficacy.

The "additional statistical analyses" of the Phase 2b study determined the hazard ratios on the PFS endpoint: HR for investigator-read scans, 0.37; HR for central lab scans, 0.59.

The company also says a Kaplan-Meier analysis "showed significant improvement in subjects treated with aldoxorubicin versus subjects treated with doxorubicin." (PR)

For the originally reported results, see here.

CYTR +10% premarket